Latest research on Lucentis

Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab has a molecular weight of approximately 48 kilodaltons and is produced by an E. coli expression system in a nutrient medium containing the antibiotic tetracycline (tetracycline is not detectable in the final product). Ranibizumab is marketed under the name Lucentis®. It is indicated for the treatment of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.

Lucentis dosage

The findings in the Safety Assessment of Intravitreous Lucentis for AMD (SAILOR)15 study also suggested a dose-related response, with greater improvements in visual acuity (VA) in patients receiving ranibizumab 0.5 mg versus 0.3 mg. [source, 2015]
All patients underwent an initial loading dose of three-monthly intravitreal injections of 0.5 mg ranibizumab (Lucentis, Novartis Pharma AG, Basel, Switzerland). [source, 2014]
Initial treatment was given as a loading dose over three months with monthly intravitral injections of 0.5 mg Ranibizumab (Lucentis). [source, 2014]
Our aim was to estimate the influence of the loading dose of ranibizumab (Lucentis) on the expression of collagen, elastin, and laminin genes in patients with the exudative form of AMD. [source, 2014]
Under the influence of the loading dose of Lucentis, the genes coding collagen type I (gene COL1A1) and collagen type VI (gene COL6A1) were overexpressed. [source, 2014]
Loss of collagen XI, after the loading dose of Lucentis, may theoretically distort renewal of the vitreous body after it is exposed to numerous iatrogenic injuries. [source, 2014]
The loading dose of Lucentis caused decreased expression of beta-laminin (LAMB4) and gamma-laminin (LAMBC2). [source, 2014]
Subsequently, we performed standard-fluence photodynamic therapy (PDT: laser fluence set at 50 J/cm2) with full-dose verteporfin (Visudyne; Novartis Pharma AG, Basel, Switzerland) in combination with an intravitreal ranibizumab (Lucentis, Genentech) (IVR) injection. [source, 2013]
Group 1 patients received 0.1 mL (2.5 mg equivalent to the intravitreal dose) of bevacizumab (Avastin), while 0.1 mL (1 mg being the same dose approved for intravitreal usage) of ranibizumab (Lucentis) was administered to the patients in group 2. [source, 2013]
In the SAILOR (Safety Assessment of Intravitreous Lucentis for AMD) study, ranibizumab doses of 0.3 and 0.5 mg were evaluated without a control group. [source, 2012]